BRPI0518205A - uso de (4'-trifluorometilfenil)-amida de ácido (z)-2-ciano-3-hidróxi-but-2-enóico para o tratamento de doença inflamatória do intestino - Google Patents

uso de (4'-trifluorometilfenil)-amida de ácido (z)-2-ciano-3-hidróxi-but-2-enóico para o tratamento de doença inflamatória do intestino

Info

Publication number
BRPI0518205A
BRPI0518205A BRPI0518205-0A BRPI0518205A BRPI0518205A BR PI0518205 A BRPI0518205 A BR PI0518205A BR PI0518205 A BRPI0518205 A BR PI0518205A BR PI0518205 A BRPI0518205 A BR PI0518205A
Authority
BR
Brazil
Prior art keywords
treatment
inflammatory bowel
bowel disease
trifluoromethylphenyl
cyano
Prior art date
Application number
BRPI0518205-0A
Other languages
English (en)
Inventor
Richard D Scheyer
Scot D Styren
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0518205A publication Critical patent/BRPI0518205A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

USO DE (4'-TRIFLUOROMETILFENIL)-AMIDA DE áCIDO (Z)-2-CIANO-3-HIDRóXI-BUT-2-ENóICO PARA O TRATAMENTO DE DOENçA INFLAMATóRIA DO INTESTINO. A presente invenção refere-se ao uso de um composto de fórmula I no tratamento de pacientes para os sintomas de doença inflamatória do intestino, incluindo doença de Crohn e colíte ulcerativa.
BRPI0518205-0A 2004-10-19 2005-10-18 uso de (4'-trifluorometilfenil)-amida de ácido (z)-2-ciano-3-hidróxi-but-2-enóico para o tratamento de doença inflamatória do intestino BRPI0518205A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62025504P 2004-10-19 2004-10-19
PCT/US2005/037161 WO2006044741A1 (en) 2004-10-19 2005-10-18 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
BRPI0518205A true BRPI0518205A (pt) 2008-11-04

Family

ID=35636963

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518205-0A BRPI0518205A (pt) 2004-10-19 2005-10-18 uso de (4'-trifluorometilfenil)-amida de ácido (z)-2-ciano-3-hidróxi-but-2-enóico para o tratamento de doença inflamatória do intestino

Country Status (13)

Country Link
US (1) US20070197643A1 (pt)
EP (1) EP1804782A1 (pt)
JP (1) JP2008517059A (pt)
KR (1) KR20070065888A (pt)
CN (1) CN101043883A (pt)
AU (1) AU2005295511A1 (pt)
BR (1) BRPI0518205A (pt)
CA (1) CA2584655A1 (pt)
IL (1) IL182591A0 (pt)
MX (1) MX2007004265A (pt)
RU (1) RU2007118691A (pt)
SG (1) SG142305A1 (pt)
WO (1) WO2006044741A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006268238A1 (en) 2005-07-11 2007-01-18 Medtronic Ablation Frontiers Llc Low power tissue ablation system
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
CA2772275A1 (en) * 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
JOP20190207A1 (ar) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
KR20010042804A (ko) * 1998-04-17 2001-05-25 파커 휴우즈 인스티튜트 비티케이 억제제와 그들의 동정 방법 및 용도
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2004536786A (ja) * 2001-03-02 2004-12-09 メディミューン，インコーポレイテッド インテグリンαｖβ３拮抗薬を他の予防薬もしくは治療薬と組み合わせて投与することによる炎症性疾患または自己免疫疾患の予防または治療方法
ATE396719T1 (de) * 2001-04-05 2008-06-15 Aventis Pharma Inc Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
EP1534666A1 (de) * 2002-09-06 2005-06-01 Schebo Biotech AG Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes

Also Published As

Publication number Publication date
JP2008517059A (ja) 2008-05-22
IL182591A0 (en) 2007-09-20
CN101043883A (zh) 2007-09-26
MX2007004265A (es) 2008-03-04
AU2005295511A1 (en) 2006-04-27
US20070197643A1 (en) 2007-08-23
KR20070065888A (ko) 2007-06-25
SG142305A1 (en) 2008-05-28
RU2007118691A (ru) 2008-11-27
WO2006044741A1 (en) 2006-04-27
EP1804782A1 (en) 2007-07-11
CA2584655A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
BRPI0518205A (pt) uso de (4'-trifluorometilfenil)-amida de ácido (z)-2-ciano-3-hidróxi-but-2-enóico para o tratamento de doença inflamatória do intestino
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
WO2007022518A3 (en) New uses of glucoregulatory proteins
BRPI0510084A (pt) benzoxazina para tratamento de doenças do trato respiratório
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
DK2020996T3 (da) Fremgangsmåder og sammensætninger til behandling af hæmatologiske sygdomme
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
DE502005010427D1 (de) Physiologisch aktive zusammensetzung gegen diabetes
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
EA200802173A1 (ru) Производные терфенила для лечения болезни альцгеймера
RU2009120992A (ru) Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции
MA33721B1 (fr) Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek
DK2040703T3 (da) Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf
UY29859A1 (es) Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica
NO20076405L (no) Anvendelse av 24-nor-UDCA
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual
BRPI0509667B8 (pt) composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto
GB0606015D0 (en) therapeutic agents

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.